Last reviewed · How we verify
NCT04992013
Niraparib in Tumors Metastatic to the CNS
Phase 2 trial testing Niraparib in Metastatic Cancer in 20 participants. Participants enrolled and being followed up; not accepting new ones.
1 December 2026
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 5 April 2022 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Niraparib (niraparib) — full drug profile →
Conditions studied
- Metastatic Cancer — all drugs for Metastatic Cancer →
- Central Nervous System Cancer — all drugs for Central Nervous System Cancer →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Metastatic Cancer or Central Nervous System Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). * This research study involves the study drug niraparib.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, et al · · 2022 · cited 25× · PMID 36533080 · DOI 10.3389/fmolb.2022.1073797 -
Leveraging translational insights toward precision medicine approaches for brain metastases.
Kim AE, Nieblas-Bedolla E, de Sauvage MA, Brastianos PK. · · 2023 · cited 14× · PMID 37491527 · DOI 10.1038/s43018-023-00585-0 -
Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing.
Kim T, Lee A, Ahn S, Park JS, et al · · 2024 · cited 8× · PMID 38317486 · DOI 10.14791/btrt.2023.0036 -
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
Scotto G, Borella F, Turinetto M, Tuninetti V, et al · · 2021 · cited 7× · PMID 34943916 · DOI 10.3390/cells10123408
Verify or expand the search:
- PubMed search for NCT04992013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Niraparib
Trials testing the same drug.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
- NCT06887933 — A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ov · Phase 4 · not yet recruiting
- NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · Phase 1, PHASE2 · withdrawn
Other recruiting trials for Metastatic Cancer
Currently open trials in the same condition.
- NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
- NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
- NCT06963723 — Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer · NA · recruiting
- NCT06311851 — Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases · Phase 1, PHASE2 · recruiting
- NCT07011862 — COBRA: Cancer, Older Adults, Balance and Resistance Activities · NA · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04992013 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04992013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing